Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Authors' conclusion
Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-h energy intake, substrate utilization, and energy expenditure.
Study context
- Population
- People with T2D
- Participants
- 45 / 44 / 28
- Comparison
- Tirzepatide 15 mg vs semaglutide 1 mg vs placebo
- Tirzepatiden = 45
- Semaglutiden = 44
- Placebon = 28reference
Methodological detailsdouble-blind, parallel-arm
- Double-blind
- Parallel-arm
Primary result
As reported in the abstract
Body weight, body composition, appetite and energy intake · week 28
- Tirzepatide significantly reduced body weight vs placebo and semaglutide, with greater fat mass reduction
- Tirzepatide and semaglutide significantly reduced appetite vs placebo
- Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide
Original publication
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →